Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trialAndreas Glenthøj, Wilma Barcellini, Sarah Gheuens et al.|The Lancet Haematology|2022Cited by 49
Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiencyEduard J. van Beers, Kevin H.M. Kuo, Hanny Al‐Samkari et al.|Blood Advances|2024Cited by 10
Long-Term Improvements in Patient-Reported Outcomes in Patients with Pyruvate Kinase Deficiency Treated with MitapivatKevin H.M. Kuo, Hanny Al‐Samkari, Rachael F. Grace et al.|Blood|2022Cited by 4
Mitapivat Improves Ineffective Erythropoiesis and Reduces Iron Overload in Patients with Pyruvate Kinase DeficiencyEduard J. van Beers, Kevin H.M. Kuo, Hanny Al‐Samkari et al.|Blood|2021Cited by 3
Clinically meaningful improvements in patient‐reported outcomes in mitapivat‐treated patients with pyruvate kinase deficiencyKevin H.M. Kuo, Hanny Al‐Samkari, Rachael F. Grace et al.|American Journal of Hematology|2024Cited by 2